Cowen and Company reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report report published on Friday, November 3rd, The Fly reports. They currently have a $151.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $117.00.
A number of other research firms have also issued reports on ALNY. Needham & Company LLC restated a buy rating and set a $152.00 price target (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. B. Riley initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They set a buy rating and a $240.00 price target on the stock. Piper Jaffray Companies reaffirmed an overweight rating and set a $14.71 price objective (down from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. FBR & Co initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a buy rating and a $150.00 price objective on the stock. Finally, Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and boosted their price objective for the company from $62.00 to $163.00 in a research report on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $121.85.
Alnylam Pharmaceuticals (ALNY) traded up $0.32 during midday trading on Friday, hitting $132.33. 771,751 shares of the company were exchanged, compared to its average volume of 1,132,019. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.
ILLEGAL ACTIVITY WARNING: This story was first published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://baseballnewssource.com/markets/alnylam-pharmaceuticals-inc-alny-receives-outperform-rating-from-cowen-and-company/1756860.html.
In related news, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 289,797 shares of company stock valued at $34,422,712. 4.30% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. QS Investors LLC raised its stake in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the last quarter. Prudential Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter valued at $215,000. CIBC Asset Management Inc acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $221,000. Finally, Neuberger Berman Group LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $229,000. Hedge funds and other institutional investors own 86.04% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.